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Abstract 8 
The last few decades have witnessed a global rise in the number of older people. Despite this 9 
demographic shift, morbidity within this population group is high. Many factors influence healthspan; 10 
however an obesity pandemic is emerging as a significant determinant of older peoples’ health. It is 11 
well established obesity adversely effects several metabolic systems. However, due to its close 12 
association with overall cardiometabolic health, the impact obesity has on cholesterol metabolism needs 13 
to be recognised. The aim of this review is to critically discuss the effects obesity has on cholesterol 14 
metabolism and to reveal its significance for healthy ageing. 15 
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1. Introduction  28 
In 2030 older people (persons aged ≥60 years) are projected to account for almost 20% of the global 29 
population(1). Despite this demographic shift in favour of older people, morbidity among this group is 30 
high(2). Many factors impact older peoples’ health; however an obesity pandemic is emerging as a 31 
significant global health concern(3; 4; 5; 6; 7). Microcosmically, the UK illustrates the extent of the global 32 
obesity problem. Among females aged 65-74 years in the UK 30% have a body mass index (BMI) ≥30 33 
kg/m2, and are categorised as obese(8). The problem is even more pronounced among their male 34 
counterparts, as 33% of males are categorised as obese within this age group(8). The problem extends to 35 
those aged ≥75 years, as 28% of females are obese, while 23% of males are obese in this age group. 36 
From a public health perspective these figures are alarming because obesity adversely effects several 37 
metabolic systems, and is synonymous with many conditions including, cancer, type 2 diabetes mellitus 38 
(T2DM), hypertension and dyslipidemia(9; 10; 11). However, due to its close association with overall 39 
cardiometabolic health, the impact obesity has on cholesterol metabolism needs to be recognised(12; 13). 40 
The aim of this review is to critically discuss the effects obesity has on cholesterol metabolism and to 41 
reveal its significance for healthy ageing. 42 
 43 
2. An overview of cholesterol metabolism 44 
Figure 1 outlines that cholesterol balance is maintained by the body responding to changes in ingestion, 45 
absorption, synthesis and excretion(14). Humans ingest a modest amount of dietary cholesterol (DC), 46 
which mixes with intestinal cholesterol(15). Absorption is controlled by cholesterol ester hydrolase 47 
which liberates cholesterol esters (CE), facilitating the inclusion of free cholesterol (FC) into bile acid 48 
micelles(16). The intestinal protein Niemann-Pick C1-Like 1 (NPC1L1) mediates cholesterol absorption 49 
into the enterocyte by clathrin-mediated endocytosis(17). ATP-binding cassette (ABC) transporters G5 50 
and G8 (ABCG5/G8) control the efflux of cholesterol from the enterocytes to the lumen(18). Within the 51 
enterocyte, acetyl CoA acetyltransferase 2 (ACAT2) re-esterifies cholesterol(19), which is combined 52 
with apolipoprotein B-48 (apoB-48), triglycerides (TGs) and phospholipids, to generate a 53 
chylomicron(20). Upon entering the bloodstream, chylomicrons are acted on by lipoprotein lipase (LPL), 54 
which catalyses their TGs, liberating free fatty acids (FFAs)(21). Chylomicron remnants are removed 55 
from the circulation by hepatic remnant receptors(22).  56 
 57 
The liver is the main site of cholesterol synthesis(23), providing cholesterol and TGs for the assembly of 58 
very low density lipoproteins (VLDLs)(24). In the plasma, LPL hydrolyses VLDLs to low density 59 
lipoproteins (LDLs), via intermediate density lipoproteins (IDLs)(25). LDL-cholesterol (LDL-C) is 60 
removed by the LDL receptor (LDLr)(26) and LDLr-related protein 1 (LRP1)(27). This process is 61 
governed by intracellular sterol levels(28). Increasing intracellular cholesterol activates, insulin-induced 62 
genes (Insigs) proteins. Insig-1 and Insig-2 bind to sterol regulatory element-binding protein cleavage-63 
activating protein (SCAP) in the endoplasmic reticulum (ER), restricting the migration of the SCAP/ 64 
sterol regulatory element-binding protein (SREBP) complex to the Golgi(29; 30). When sterol levels drop, 65 
SREBP-2 migrates to the Golgi where it is cleaved by subtilisin kexin isozyme/Site-1 protease (SKI-66 
1/S1P), and the intramembranous metalloprotease Site-2 protease (S2P)(31). This releases the NH-67 
terminal domain of SREBP-2 from the membrane. Two N-terminal fragments dimerize, then interact 68 
with importin-β, before entering the nucleus, to activate SREBP-2-regulated gene promoters(32). A 69 
further regulatory point involves LDLr synthesis. Nuclear SREBP-2 increases the transcription of 70 
proprotein convertase subtilisin/kexin type 9 (PCSK9)(33). PCSK9 reduces the number of LDLrs by 71 
increasing their metabolism, and subsequent degradation, restricting LDL uptake(33). High cellular 72 
cholesterol levels suppress SREBP-2 release from the ER, thus PCSK9 transcription is reduced, which 73 
subsequently increases LDLRr levels(34). The synchronised interplay of SREBP-2 induced transcription 74 
of both LDLr and PCSK9 regulates circulating LDL-C levels. Additionally, cholesterol entering a 75 
hepatic cell as part of LDL triggers ACAT2(26), which catalyses FC to CE(19), and this cholesterol also 76 
activates cholesterol 7α - hydroxylase (CYP7A1), the rate-limiting enzyme of bile acid synthesis(35).  77 
By disrupting any of the mechanisms I have discussed, obesity has the potential to provoke a rise in 78 
plasma LDL-C. Elevated LDL-C levels are inexorably linked to an increased risk of atherosclerotic-79 
cardiovascular disease (CVD)(36; 37; 38). Moreover, emerging evidence suggests suboptimal LDL-C 80 
levels, in tandem with elevated serum uric acid, could present an increased risk of developing 81 
hypertension or metabolic syndrome(39; 40).   82 
 83 
 84 
A further important aspect of cholesterol metabolism is reverse cholesterol transport (RCT). RCT 85 
removes excess cholesterol from peripheral tissue(41). High density lipoproteins (HDLs) are central to 86 
this. HDLs “mop up” excess cholesterol, generating HDL-cholesterol (HDL-C)(42). Central to RCT is 87 
the ferrying of FC and phospholipids to lipid-free apo A-I to form nascent pre-β HDL particles, in a 88 
process primarily regulated by ABCA1(43; 44). Nascent HDLs progress to mature HDLs due to the 89 
esterification of cholesterol by lecithin-cholesterol acyltransferase (LCAT)(45). Cholesterol within 90 
HDLs can follow one of two routes to the liver. HDLs can go directly to the liver and deposit their 91 
cholesterol by interacting with scavenger receptor class B, type 1 (SR-B1) receptors(46). Secondly, 92 
cholesterol can be transferred to the liver via the action of cholesteryl ester transfer protein (CETP), 93 
which redistributes cholesterol to LDL and VLDL(47). Regardless of the route, HDLs transfer cholesterol 94 
to the liver, where it can be effluxed directly as cholesterol or converted to bile salts(48). It can then be 95 
excreted during enterohepatic circulation. Consequently, RCT is regarded as antiatherogenic(49);this is 96 
underscored by studies which have revealed an inverse relationship between HDL-C levels and the 97 
onset of premature CVD(50; 51). Intriguingly, HDL’s antiatherogenic role is thought to be enhanced 98 
further by possessing antioxidant properties(52). As with the mechanisms which regulate LDL-C levels, 99 
if obesity interferes with the processes underpinning RCT, this has the potential to modulate an 100 




3. Obesity and cholesterol metabolism 105 
 106 
3.1 Cholesterol absorption 107 
In pioneering work, Miettinen and Kesäniemi (1989) identified a negative correlation between the 108 
fractional absorption of DC and obesity in middle aged men; although, a mechanistic explanation for 109 
this result was not immediately apparent(53). In a follow up investigation cholesterol absorption was also 110 
found to  be  inhibited in obese middle aged males (BMI >31 kg/m2)(54). On this occasion two 111 
explanations were proposed for this finding. It was posited labelled DC could have contributed to sub-112 
normal cholesterol absorption. Secondly, it was suggested that cholesterol absorption was inhibited by 113 
expanded biliary secretion. However, the precise reason why obesity inhibited cholesterol absorption 114 
remained unclear. More recent studies have added further intrigue to this puzzle. It has been found that 115 
treatment of obese hypercholesterolemic subjects with the NPC1L1 inhibitor, Ezetimibe, improved the 116 
lipid profile and insulin resistance (IR) in these subjects(55; 56). This suggests obesity could in fact 117 
increase cholesterol absorption in obese subjects rather than inhibiting it, and an arbiter of this change 118 
could be NPC1L1. If obesity does increase cholesterol absorption, this effect could also be induced by 119 
provoking a rise in circulating bile acids. For example, Vincent et at. (2013) found that the post-prandial 120 
bile acid response is increased in obese male and female patients with T2DM compared to age-matched 121 
normoglycaemic individuals(57). Further evidence that obesity influences bile acid metabolism comes 122 
from studies of the gut microbiome(58).  For instance, in one study it was found that bile salt hydrolase 123 
(BSH) is the arbiter of host-microbiome interactions which modulated weight gain, and lipid 124 
metabolism in a murine model(59). Specifically, the expression of cloned BSH enzymes in the 125 
gastrointestinal tract of gnotobiotic or conventionally raised mice significantly modified plasma bile 126 
acid signatures and regulated the transcription of important genes involved in cholesterol metabolism 127 
(Abcg5/8) both hepatically and intestinally. Moreover, high-level expression of BSH in conventionally 128 
raised mice resulted in a significant drop in host weight gain, plasma cholesterol levels, and hepatic 129 
TGs.  As an adjunct to this finding it has been shown that the farnesoid X receptor (FXR) has a central 130 
role to play in modulating host-microbiome dialogue.  For instance, mouse models of diet-induced 131 





3.2 Cholesterol synthesis 137 
Cholesterol synthesis is also affected by obesity; sterol-balance studies have shown increased weight 138 
gain results in a higher rate of cholesterol synthesis(62; 63). It is uncertain how weight gain induces a 139 
higher rate of cholesterol synthesis. However, it is important to acknowledge that hepatic HMGCR 140 
increases in obese subjects(64). This would naturally result in an increase in hepatic cholesterol 141 
production; something which has been observed in obese subjects(65). For example, in a study involving 142 
17 morbidly obese middle-aged males, it was found that the activity, and mRNA levels of HMGCR, 143 
was higher in the obese subjects, when compared to lean control group(66). Moreover, the activity and 144 
mRNA level of cholesterol 7 alpha-hydroxylase, also increased compared to controls. The activity of 145 
ACAT2, and LDLr mRNA levels were elevated in these subjects. Such alterations have the potential to 146 
impact the normal functioning of hepatic LDLr. For example, it was also found in this study that the 147 
binding of LDL to the LDLr was reduced by fifty percent when compared with controls(66).  148 
 149 
3.3 Hepatic free cholesterol/ bile acid accumulation and Non-alcoholic fatty liver disease 150 
Non-alcoholic fatty liver disease (NAFLD) encompasses a number of hepatic pathologies, from fatty 151 
liver disease to non-alcoholic steatohepatitis (NASH); a condition which can progress to cirrhosis(67; 68; 152 
69; 70; 71). NAFLD has a higher occurrence in males than females, and its prevalence increases with age(72; 153 
73). NAFLD is closely associated with IR and hyperinsulinemia and is prevalent in 70-80% of obese 154 
individuals(74). Moreover, it has recently been associated with key parameters of cardiovascular health, 155 
including arterial stiffness(75). Traditionally, NAFLD has been associated with increased hepatic TGs, 156 
however in recent years there has been growing evidence linking altered cholesterol metabolism with 157 
the aetiology of NAFLD(76; 77; 78). For instance, hepatic FC accumulates in obese diabetic mice and 158 
results in steatohepatitis(79). Most recently in mice it has been found that found that hepatic cholesterol, 159 
but not hepatic TG, increased with age(80). Focusing on humans the intake of high levels of DC have 160 
been associated with NASH(81; 82). Mechanistically, it would appear cholesterol synthesis is upregulated 161 
in NAFLD. This was demonstrated by a study which examined the expression of an array of genes 162 
associated with cholesterol metabolism(83). In the investigation, 20 middle aged subjects with NAFLD 163 
(mean BMI 34.1 kg/m2) and NASH (mean BMI 34.2 kg/m2) were compared to 20 obese controls (33.2 164 
kg/m2) and 6 lean normal controls (mean BMI 21.4 kg/m2). It was found NAFLD was associated with 165 
increased SREBP-2 maturation, HMGCR expression and decreased phosphorylation of HMGCR. 166 
Additionally, cholesterol ester hydrolase was increased, while ACAT2 remained unchanged. Moreover, 167 
LDLr expression decreased significantly. Also, HMGCR expression was correlated with FC, histologic 168 
severity of NAFLD and LDL-C levels. Bile acid homeostasis is also affected as a result of NAFLD(84). 169 
Individuals with NASH have elevated levels of bile acids which can accumulate hepatically(85). Bile 170 
acid signalling is regulated by the Farnesoid X receptor (FXR), which contributes to overall cholesterol 171 
metabolism (84). Interestingly, it has been shown in mice that the gut microbiota can modulate obesity 172 
via this receptor. The gut microbiota promoted weight gain and hepatic steatosis in an FXR-dependent 173 
manner between Fxr-/- and wild-type mice (60). Moreover, bile acid profiles and the composition of 174 
faecal microbiota differed between Fxr-/- and wild-type mice. The finding that the gut microbiota 175 
induced liver steatosis in an FXR-dependent manner was suggested to be induced by the increased 176 
expression of CD36, Apolipoprotein C2, and VLDL receptor, all of which are involved in lipoprotein 177 
uptake. Thus, increased steatosis was thought to be attributed to the augmented expression of lipogenic 178 
genes or diminished expression of genes associated with fatty acid oxidation.  In terms of promoting 179 
obesity mechanistically the authors showed that the gut microbiota of Fxr-deficient mice was defined 180 
by a phylum-wide rise in Bacteroidetes and phylum-wide reduction of Firmicutes. Thus, the gut 181 
microbiota changes in response to diet and is associated with an obesity phenotype, which is mediated 182 
by FXR signalling. 183 
3.4 Lipoprotein dynamics and RCT 184 
Lipoprotein processing is significantly impaired due to obesity. Morbidly obese middle aged patients 185 
have been found to have lower expression of LPL and LRP1 in their visceral tissue(86). LPL expression 186 
was also lower in the subcutaneous adipose tissue of these subjects. The decrease in the expression of 187 
LRP1 is likely a contributing factor to the increase in plasma LDL-C, which often, but not always, 188 
accompanies obesity(87). More strikingly, obesity has regularly been associated with an increase in 189 
atherogenic small dense LDL(88; 89; 90). Obesity also lowers HDL-C regardless of age, sex or ethnic 190 
background, while an inverse association between HDL-C levels and BMI has also been observed(91; 92; 191 
93). Intriguingly, in the Framingham offspring study, the effect of increased BMI on total cholesterol 192 
and LDL-C was not as strong as it was for HDL-C(94). More recently, an inverse association has been 193 
found between LDL-C and BMI in morbidly obese subjects(95). Low levels of the major apolipoprotein 194 
component of HDL (Apo A-I) have also been found to be associated with obesity in the Framingham 195 
Offspring Study in men and women(96). Moreover, it has been revealed in a mouse model that increased 196 
Apo A-I could have an anti-obesity effect. Increased energy expenditure and up-regulation of 197 
uncoupling protein 1 in brown fat were associated with high levels of Apo A-I(97). In addition, other 198 
apolipoproteins have been shown to be influenced by obesity. Elevated levels of fasting and 199 
postprandial apo B-48 have been measured in obese human subjects(66). Obesity could also impact the 200 
functional capacity of HDL-C. For example, the antioxidant capacity of HDL appears to be 201 
compromised in obese subjects(98). Obesity interferes with other components of RCT, for example, 202 
obesity causes impairment in RCT due to reduced plasma cholesterol uptake and efflux by hepatocytes 203 
and adipocytes in ob/ob mice(99). Plasma CETP levels have also been positively correlated with 204 
obesity(100). The likely reason for this finding, is that adipose tissue is a significant source of CETP(101). 205 
Intriguingly, LCAT deficiency has been suggested to confer a degree of protection from the 206 
development of obesity. Tentative evidence for this finding comes from a study of LCAT null mice 207 
which appeared to be protected from diet-induced obesity(102). 208 
 209 
 210 
4. Commonality between obesity and ageing 211 
It is possible obesity superimposed on ageing could expedite the age associated dysregulation of 212 
cholesterol metabolism(103; 104; 105). Taking LDL-C as an example, increasing age is associated with a 213 
rise in LDL-C in males and females, in both cross-sectional(106; 107) and prospective studies(108; 109). It is 214 
not known how ageing contributes to a rise in LDL-C; however, there are solid reasons to believe a 215 
decline in the hepatic clearance rate of LDL-C is a factor(110; 111). For example, human ageing is 216 
associated with a drop in the number of hepatic LDLr(112). Obesity can also results in a rise in LDL-217 
C(113; 114), although in some observational studies it is only weakly associated(115; 116),or not associated at 218 
all(117). An obesity induced rise in LDL-C could have the same mechanistic underpinning as ageing, 219 
because it is also associated with a decline in hepatic LDLr numbers. Also similar to obesity, HDL-C 220 
levels decrease with age in humans in certain studies(118). For instance, HDL-C levels have been 221 
observed to decrease with age in both men and women in prospective studies(109; 119). Although HDL-C 222 
levels do not change with age in most cross-sectional studies(120; 121), they have been shown to decrease 223 
in others(122). A decline in HDL-C with age could be due to disrupted CETP activity. If this is the case 224 
it would be mechanistically similar to the putative effect obesity has on RCT(100). Ageing also impacts 225 
lipoprotein processing by reducing the activity of plasma LPL by as much as 55-60%(123; 124). This is 226 
similar to the metabolic affect obesity has on LPL(125). In rodents it has been found that bile acid 227 
synthesis diminishes with age(126). This is also similar to obesity because in men and women a decrease 228 
in the conversion of cholesterol to bile acids has been identified in certain studies(127; 128). However, 229 
other studies conflict with this and suggest obesity results in an increase in bile acid synthesis(129).  230 
 231 
The landscape of an obese state also resonates with the free radical theory of ageing(130). For example, 232 
obesity is associated with oxidative stress via increased generation of reactive oxygen species 233 
(ROS)(131). As visceral fat stores increase, adipocytes generate increasing levels of ROS (132). 234 
Consequently, oxidative stress results in IR within adipose and peripheral tissue(133). It has been 235 
suggested that high levels of ROS impinge on intracellular cholesterol homeostasis(134). ROS have been 236 
found to upregulate the activity of hepatic HMGCR in rodent hepatic tissue, leading to an increase in 237 
cholesterol synthesis(80; 135; 136; 137) ROS are also implicated in the pathogenesis of atherosclerosis, where 238 
oxidation of LDL is regarded as a key event in the initial stages of atherosclerosis formation(138). Despite 239 
the many parallels between obesity and ageing a number of difference do exist. In contrast to obesity it 240 
has been revealed that cholesterol absorption efficiently increases with age, however there is a paucity 241 
of evidence for this in humans and findings are confined to rodent studies(139). Mechanistically it appears 242 
ageing suppresses the expression of Abcg5 and Abcg8, and upregulates the expression of Npc1l1 in 243 
murine models(140). In rodents it has been found that bile acid synthesis declines with age(126). This 244 
contrasts with obesity. Also, unlike obesity, it has been found that hepatic ACAT2 activity decreases 245 
with age in Watanabe heritable hyperlipidemic rabbits(141).  246 
 247 
5. Diet: A key modulator of obesity and cholesterol metabolism 248 
An obese state is the result of an imbalance between the amount of calories consumed by an individual 249 
and the amount of energy they expend(142). Moreover, it is generally regarded that excess consumption 250 
of dietary fat plays a role in the development of obesity(143). Taking this a step further, a clear link 251 
between diet, cholesterol metabolism and obesity centres on the excessive intake of DC. For instance, 252 
DC has been shown to exacerbate hepatic steatosis and inflammation in obese LDLr-deficient mice(144). 253 
Moreover, in this study, the consumption of DC exacerbated hepatic macrophage infiltration, apoptosis, 254 
and oxidative stress. Excessive intake of DC has also been shown to result in the accumulation of 255 
hepatic cholesterol in obese diabetic mice(79). The accumulation of cholesterol was attributed to changes 256 
in some of the regulator mechanisms discussed previously, including the up-regulation of LDLr, via 257 
activation of SREBP-2, a drop in the conversion of cholesterol to bile acids, and suppression of bile 258 
acid excretion in bile.  259 
 260 
In addition to the intake of fat/DC, high intakes of dietary sugars have been associated with obesity and 261 
unfavourable lipid levels in both men and women(127; 128). In particular dietary fructose has emerged as 262 
an important dietary factor which contributes to the hepatic dysregulation of cholesterol metabolism (69; 263 
145). For instance, high fructose consumption increases serum PCSK9 concentrations and reduces liver 264 
LDLr protein levels in hyperlipidemic hamsters(146). In humans, it has been found that the consumption 265 
of fructose and high fructose corn syrup increases LDL-C, and apo-B in both men and women(147). 266 
Moreover, NASH is associated with animal models fed a high fat, high fructose diet(148; 149). 267 
Consumption of excessive dietary fructose has also been associated with cognitive decline in older 268 
adults(150). This is intriguing because obesity can be correlated with poor cognitive performance in older 269 
adults(151). Taking this a step further, it is possible fructose makes a mechanistic contribution to the 270 
pathogenesis of Alzheimer’s disease by interfering with lipid metabolism. For example, animal models 271 
of dementia suggest excessive consumption of fructose induce IR and promote dementia 272 
pathogenesis(152; 153; 154). This is thought to occur as follows, IR is associated with elevated plasma 273 
ceramides which interfere with lipoprotein metabolism and amyloidogenic processing resulting in the 274 
deposition of β-amyloid peptides, which is a hallmark of Alzheimer’s disease(155).  275 
 276 
In certain circumstances age could potentially offer a degree of protection against diet-induced obesity. 277 
In a recent study which compared the response of young and old mice to a Western diet (WD), it was 278 
found that old mice did not show a higher body weight or adipose tissue mass, when compared to their 279 
young counterparts(156). Significantly, and of direct relevance to the underlying hepatic health of older 280 
people, it was found that the aged mice did have a build-up of hepatic lipid on the WD.  As well as the 281 
type and amounts of nutrients consumed, it has been found that meal frequency, timing, and regularity 282 
are also associated with obesity(157). Recently this has been shown to have important implications for 283 
cholesterol metabolism. In a cross-sectional study of non-institutionalized and non-pregnant healthy 284 
Taiwanese adults (≥19-years-old) found that higher energy intake at night time is associated with 285 
elevated total and LDL-C levels(158). This was an interesting finding, although a mechanistic explanation 286 
for this discovery was not posited. Regardless, the study presents the possibility that meal timing and 287 
frequency could impact both obesity and cholesterol metabolism which is an intriguing prospect.  288 
 289 
Alcohol consumption also effects cholesterol metabolism. Evidence suggests moderate to low alcohol 290 
consumption increases levels of HDL-C and decreases levels of LDL-C (159). However, it is important 291 
to be cautious as alcohol has a limited therapeutic range and only modest drinking appears to be 292 
beneficial. This is partly due to the caloric richness of alcohol, as its excessive consumption can result 293 
in increased weight gain in certain individuals(160). Moreover, chronic alcohol intake affects lipid 294 
metabolism broadly by provoking the increased synthesis of TGs and subsequent 295 
hypertriglyceridemia(161). In addition, it has been observed that alcohol consumption decreases the 296 
activity of LPL, which is also associated with hypertriglyceridemia(162). From the perspective of HDL 297 
metabolism, in individuals with  alcohol dependence syndrome no association between plasma-HDL-298 
C and the number of drinks consumed per day has been observed in these individuals, indicating that 299 
only low level consumption of alcohol is beneficial(163). Furthermore, in a longitudinal study of alcohol 300 
consumption, the long-term effect of total alcohol consumption on the change in HDL-C was observed 301 
to be a nonlinear relationship(164). The mechanistic explanation for this is thought to centre on the 302 
pathophysiological effect of alcohol on the liver which results in a decrease in the hepatic production 303 
of HDL in these subjects(165).  304 
 305 
Alarmingly, the excessive intake of alcohol has been increasing among older people in certain 306 
populations(166). In a recent study involving a cohort of Australian males (≥ 65 years), which explored 307 
the association between alcohol intake and body composition, it was found that participants who 308 
consumed ≥5 alcoholic drinks/day had a greater BMI, fat mass index, waist circumference, percent 309 
body fat and lower lean mass than non-drinkers(167). This has metabolic consequences for older people 310 
because alcohol consumption augments lipid synthesis via sterol SREBP-1(168). This is possibly 311 
mediated by acetaldehyde, which contributes to an increase in the synthesis of SREBP-1, which in turn 312 
augments cholesterol and fat synthesis(168). Alcohol consumption has also been shown to dysregulate 313 
hepatic fatty acid oxidation(169) and decrease the secretion of VLDL(170). A drop in VLDL secretion 314 
could result in a decrease in the conversion of VLDL-C to LDL-C, and be responsible for the decrease 315 
in LDL-C associated with low to moderate alcohol intake(171). Furthermore, this mechanism could 316 
explain the decreased risk of alcohol dependence with increased LDL-C levels identified among some 317 
of the participants of a recent case control study investigating alcohol consumption and obesity(172).  318 
 319 
On the flip side of the coin, emerging research has revealed that certain novel dietary components 320 
improve both cholesterol metabolism and have anti-obesity effects. For example, a diet high in fruit and 321 
vegetables is associated with a lower risk of obesity/body adiposity(173; 174; 175). Moreover, certain 322 
components of fruits and vegetables have a favourable effect on cholesterol metabolism. For instance, 323 
soluble fibre exerts a favourable effect  by decreasing LDL-C levels(176). It has been found that 3g per 324 
day of soluble fibre can lower total and LDL-C by ~0.13 mmol/L(177). Several mechanisms have been 325 
suggested to account for this effect, including the inhibition of bile salt intestinal re-absorption, and a 326 
diminished glycemic response, which results in a drop in insulin stimulated hepatic cholesterol 327 
synthesis(178).  The gut is also thought to be the site of action of plant sterols. Plant sterols are naturally 328 
occurring compounds found in fruit and vegetables which are structurally related to cholesterol differing 329 
only in the structure of their side chains(179). Consumption of 1.8-2.0 g/day of plant sterols has been 330 
shown to lower both total and LDL-C concentrations by 10%-15% in different population groups(180; 331 
181). Although the precise mechanism by which LDL-C is lowered is uncertain, it is generally regarded 332 
that plant sterols inhibit intestinal cholesterol absorption(182).  Not only have plant sterols been associated 333 
with decreased LDL-C. More recently, the consumption of high levels of phytosterols, which includes 334 
plants sterols, have been associated with decreased rates of obesity.  For example, a recent cross-335 
sectional study of Chinese adults (18-60 years) revealed that higher consumption of phytosterols was 336 
associated with lower BMI, waist circumference, and a lower prevalence of 337 
overweight/obesity/abdominal obesity in this population group(183).  Intriguingly the administration of 338 
both phytosterols and red rice were recently studied in mildly hypercholesterolemic subjects(184). In 339 
tandem these two nutraceuticals had a more significant impact on LDL-C levels, when compared to 340 
either phytosterols or red rice on their own. Diet also has an important role to play in terms of alleviating 341 
the metabolic consequence of obesity.  Most recently, it has been shown that medium chain saturated 342 
fatty acids (MCSFA) could illicit a degree of protection against obesity-induced comorbidities such as 343 
diabetes in obesogenic mice(185). Moreover, in a rat model it has been found that MCSFA could help 344 
prevent NAFLD(186). Mechanistically, it is thought the beneficial effects of MCSFA consumption could 345 
be induced via their preferential β-oxidation over long chain saturated fatty acids(187).  A further way 346 
diet has been suggested to provide a means of treating obesity is by modulating the gut microbiome. 347 
For instance, in an obese population which adhered to a Mediterranean diet (MD) for a year, it was 348 
found that the MD exerted a protective effect against T2DM development by modulating specific 349 
changes in the gut microbiota. Specifically, this involved increasing the abundance of Faecalibacterium 350 
prausnitzii and Roseburia species. 351 
 352 
 353 
 6. Cholesterol metabolism and obesity in older people  354 
Certain individuals have a metabolic profile which does not appear to be overtly affected by obesity. 355 
Such individuals are known as “metabolically healthy obese" (MHO)(188). In a study which investigated 356 
obesity in the US population, it was found 31.7% of obese adults (~19.5 million), were MHO(189). The 357 
prevalence of metabolically healthy older individuals was 14.3% among those aged 65-79 years, and 358 
22.1% among those ≥80 years. Healthy participants were defined by having 0 or 1 cardiometabolic 359 
abnormality. Unhealthy individuals were defined as having ≥2 cardiometabolic abnormalities. Among 360 
individuals with ≥2 metabolic abnormalities, the two most common cardiometabolic risk factor 361 
combinations, were high TG level/low HDL-C level and high blood pressure/high glucose level. In a 362 
similar investigation it was found that among participants with ⩽1 metabolic abnormality, obesity was 363 
associated with a greater risk of developing multiple metabolic abnormalities(190). Significantly, lipid 364 
metabolism was also key, as TG and HDL-C levels predicted an individual’s progression to a 365 
metabolically unhealthy obese (MUHO) state. Within obesity research, a further puzzle exists; there are 366 
situations where being overweight/mildly obese appears to be beneficial. This is known as the “obesity 367 
paradox”(191). In an ageing context, the obesity paradox appears to confer a survival advantage in older 368 
patients (generally those >50 years) who have conditions such as, CVD, arthritis and kidney disease(192).  369 
Focusing specifically on cholesterol metabolism, and its intersection with the obesity paradox, normal 370 
total serum cholesterol levels have been reported in morbidly obese individuals. In a study of 3,312 371 
women (≥ 18 years) it was found the percentage of individuals with normal total serum cholesterol 372 
levels (<200 mg/dL) decreased with increasing BMI, from 55% in those with a BMI <20 kg/m2 to 28% 373 
in women with a BMI of 30-35 kg/m2(193). Total serum cholesterol >7.75 mmol/l was found in 2% of 374 
individuals with a BMI <20 kg/m2, but in 6% of the group with a BMI between 30 and 35 kg/m2. Among 375 
morbidly obese women (BMI >40 kg/m2), 39% had total serum cholesterol levels <5 mmol/l. Thus, it 376 
would appear in morbidly obese women, there is a significant number of individuals with normal total 377 
serum cholesterol levels. Such findings were also identified in a study which examined individuals (20–378 
64 years) with a BMI in the range 34-77 kg/m2(194). It was found that mean total cholesterol levels in the 379 
obese group fell with increasing BMI. Moreover, LDL-C levels were lower in obese men (3.65 mmol/l 380 
versus the control group, 4.17 mmol/l).  381 
 382 
The association between obesity and cholesterol metabolism has been studied to a limited extent in the 383 
oldest old (individuals ≥80 years). Despite this, the oldest old who are obese have a higher prevalence 384 
of morbidity(195). In a study which examined the oldest old among a group aged 60-85 years, it was 385 
reported that obesity was associated with shorter survival plus a higher incidence of coronary heart 386 
disease and T2DM(196). When cholesterol metabolism has been examined in the oldest old some 387 
intriguing findings have been revealed. In the Leiden 85-Plus Study it was observed that both high and 388 
low levels of LDL-C had a similar impact on mortality risk(197). Interestingly, this finding occurred 389 
despite CVD being the main cause of mortality in these subjects. Similar observations have been 390 
identified in several other studies which have examined the lipoprotein profile of the oldest old(198; 199). 391 
Interestingly, during a three year follow up study involving the Chinese oldest old it was found that for 392 
each 1 mmol/L increase of LDL-C concentration there was a corresponding 19% decrease in 3-year all-393 
cause mortality (200). These findings are intriguing and require a biological explanation. The oldest old 394 
in general are in a state of multi-morbidity(201). Based on this premise it is logical that low levels of 395 
LDL-C could be one particular clinical manifestation of underlying multi-morbidity. Ageing 396 
superimposed on cholesterol metabolism in a MUHO individual or a metabolically unhealthy normal 397 
weight individual could theoretically contribute to a drop in LDL-C. The conceptual framework 398 
outlined in figure 2 suggests an obese state/poor metabolic health combined with an age associated rise 399 
in hepatic ROS levels results in a rise in HMGCR activity(202; 203). In a normolipidemic individual this 400 
would result in rise in LDL-C due to the homeostatic down-regulation of LDLr synthesis. However, if 401 
there is also an age associated decrease in ACAT2 activity, this reduces the conversion of FC to CE. 402 
Consequently, VLDL-C production would drop and there would be a concomitant reduction in LDL-403 
C. As intracellular levels of FC accumulate and oxidative stress progresses, this state could advance to 404 
NAFLD(204). As there is a strong association between NAFLD(205) and CVD(206), this in theory could 405 
increase an older persons risk of mortality, and help to account for the association between low levels 406 
of LDL-C and increased risk of mortality, which has been observed in certain studies involving the 407 
oldest old.   408 
 409 
7. Conclusions 410 
Obesity among older people has increased significantly. This review has revealed that obesity has a 411 
pleiotropic effect on cholesterol metabolism. Obesity affects cholesterol absorption, synthesis, 412 
lipoprotein processing, and results in the accumulation of cholesterol hepatically. Many of the changes 413 
are similar to how ageing intersects with cholesterol metabolism, and it can be suggested an obese state 414 
superimposed on ageing has the potential to exacerbate the dysregulation of cholesterol metabolism, 415 
which occurs with advancing age. This review also revealed diet as a key factor which links an obese 416 
state to important changes which occur in hepatic cholesterol metabolism. In particular the excessive 417 
intake of dietary lipids and fructose were highlighted as key factors which underpin conditions such as 418 
NAFLD. Careful attention needs to be placed on this association. This review also highlighted a number 419 
of anomalies which exist in this field. Firstly, there are certain individuals who, despite being in an 420 
obese state, appear to be normolipidemic, and it is not immediately clear why this is the case. The 421 
second anomaly centres on the oldest old. In particular the association between low levels of LDL-C 422 
and an increased risk of mortality, which has been observed in a number of studies. A tentative 423 
explanation for this association was presented, which centred on obesity/an unhealthy metabolic state 424 
and its intersection with ageing as important factors underpinning this anomaly. However, this is only 425 
one possible explanation and to fully elucidate this intriguing anomaly, it is necessary for the dynamics 426 
of cholesterol metabolism in the oldest old to be investigated to a much greater extent. To date there 427 
has been paucity of research in this area. Finally, this review has raised a broader question which relates 428 
to the public health challenge surrounding an ageing global population which is becoming increasingly 429 
obese.   There is no straightforward solution to this problem. However, one possible strategy could 430 
involve adopting public health initiatives which target middle aged individuals and educating them 431 
about the deleterious health implications of being overweight/obese. Increased awareness among this 432 
group could lead to better health in later life. To this end it is vital public health interventions are 433 
initiated which make both younger people and middle-aged individuals cognisant of appropriate 434 
lifestyle choices which optimise their chances of growing old healthily. If this issue is not addressed in 435 
coming years, more and more people will reach old age in poor metabolic heath due to being obese.  436 
 437 
 438 
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List of Figures 913 
Figure 1: Overview of whole-body cholesterol metabolism. Cholesterol metabolism is maintained by 914 
an array of regulatory processes which control absorption, synthesis, hepatic lipoprotein production, 915 
lipoprotein uptake and reverse cholesterol transport. The signs indicate where obesity has been shown 916 
to impact cholesterol metabolism. Note: cholesterol absorption has both a positive and negative sign 917 
associated with it, to indicate that certain studies have found that obesity decreases cholesterol 918 
absorption while other have found the opposite effect. Abbreviations: ABCA1, ATP-binding cassette 919 
transporter; Acetyl-CoA, acetyl coenzyme A; ABCG5/G8, ATP-binding cassette (ABC) transporters 920 
G5 and G8; ACAT2, acetyl CoA acetyltransferase 2; CETP, cholesteryl ester transfer protein; 921 
CYP7A1, cholesterol 7 alpha-hydroxylase; IDL, intermediate density lipoprotein; HDL, high density 922 
lipoprotein; HMG-CoA, 3-hydroxy-3-methylglutaryl-CoA; HMGCR, HMG-CoA reductase; LCAT, 923 
lecithin–cholesterol acyltransferase; LDL, low density lipoprotein; NPC1L1, Niemann-Pick C1-Like 924 
1; PCSK9, proprotein convertase subtilisin/kexin type 9; SCAP, sterol regulatory element-binding 925 
protein cleavage-activating protein; SREBP-2, sterol regulatory element-binding protein 2; scavenger 926 
receptor, class B type 1(SR-B1); VLDL, very low density lipoprotein.  927 
 928 
 929 
Figure 2: Conceptual model of obesity/ageing induced changes to hepatic cholesterol metabolism 930 
which could result in low levels of LDL-C. A metabolic feature which has been observed in a number 931 
of studies involving the oldest old. Abbreviations: Acetyl-CoA, acetyl coenzyme A; ACAT2, acetyl 932 
CoA acetyltransferase 2; CETP, cholesteryl ester transfer protein; CYP7A1, Cholesterol 7 alpha-933 
hydroxylase; IDL, intermediate density lipoprotein; HDL, high density lipoprotein; HMG-CoA, 3-934 
hydroxy-3-methylglutaryl-CoA; HMGCR, HMG-CoA reductase; LCAT, lecithin–cholesterol 935 
acyltransferase; LDL, low density lipoprotein; MUHO, metabolically unhealthy obese; ROS, reactive 936 
oxygen species; SREBP-2,scavenger receptor, class B type 1(SR-B1); VLDL, very low density 937 
lipoprotein. 938 
